Exploring Crinetics Pharmaceuticals, Inc. (CRNX) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Crinetics Pharmaceuticals, Inc. (CRNX) and what's driving their interest? As of December 31, 2024, institutional investors held a significant 93.68% of the company's stock, while insiders owned about 2.04%, and public companies and individual investors held approximately 4.28%. Major players like Vanguard, FMR, and BlackRock hold substantial positions, with Vanguard holding 9,089,391 shares as of December 31, 2024. What strategies are these key investors employing, and how might their decisions impact the future of CRNX?

Crinetics Pharmaceuticals, Inc. (CRNX) Who Invests in Crinetics Pharmaceuticals, Inc. (CRNX) and Why?

Understanding the investor profile of Crinetics Pharmaceuticals, Inc. (CRNX) provides valuable insights into the market's perception of the company. Investors are drawn to CRNX for various reasons, influenced by the company's growth prospects, strategic market positioning, and overall investment strategies.

Key Investor Types:

The investor base of Crinetics Pharmaceuticals, Inc. (CRNX) is diverse, encompassing retail investors, institutional investors, and hedge funds. Each type brings different investment philosophies and objectives.

• Retail Investors: These individual investors often look for growth potential and may be influenced by positive clinical trial results or media coverage.
• Institutional Investors: These include mutual funds, pension funds, and insurance companies. They typically invest for long-term capital appreciation and stability.
• Hedge Funds: These funds tend to employ more aggressive strategies, seeking short-term gains through trading opportunities arising from market volatility or specific company events.

Investment Motivations:

Several factors attract investors to Crinetics Pharmaceuticals, Inc. (CRNX). These motivations often align with the company's potential and strategic initiatives.

• Growth Prospects: Investors are drawn to CRNX due to its promising pipeline of drug candidates and potential for significant revenue growth. Positive clinical trial outcomes and regulatory approvals can act as major catalysts.
• Market Position: The company's position in the competitive pharmaceutical landscape, particularly its focus on specific therapeutic areas, influences investor confidence. A strong market presence can lead to increased investment.

Investment Strategies:

Investors in Crinetics Pharmaceuticals, Inc. (CRNX) adopt various strategies depending on their risk tolerance and investment goals.

• Long-Term Holding: Many institutional investors and some retail investors adopt a long-term holding strategy, banking on the company's future success and potential for substantial returns over time.
• Short-Term Trading: Hedge funds and some retail investors engage in short-term trading, capitalizing on price fluctuations caused by news events, clinical trial updates, or market sentiment.
• Value Investing: Some investors may view CRNX as undervalued based on its assets, pipeline, and future earnings potential, leading them to invest with the expectation of long-term value appreciation.

To gain more insight into the company's goals, you might be interested in: Mission Statement, Vision, & Core Values of Crinetics Pharmaceuticals, Inc. (CRNX).

Crinetics Pharmaceuticals, Inc. (CRNX) Institutional Ownership and Major Shareholders of Crinetics Pharmaceuticals, Inc. (CRNX)

Institutional ownership in Crinetics Pharmaceuticals, Inc. (CRNX) plays a significant role in the company's stock performance and overall strategy. Examining the major shareholders and their recent activities provides valuable insights into market sentiment and potential future movements.

Here's a breakdown of what we know about Crinetics Pharmaceuticals, Inc. (CRNX) institutional ownership:

• Top Institutional Investors: Identifying the top institutional investors reveals who has the most influence on Crinetics Pharmaceuticals, Inc. (CRNX). These major players often include mutual funds, hedge funds, and pension funds.
• Shareholding Trends: Analyzing whether these institutions have been increasing or decreasing their positions helps gauge the overall market confidence in Crinetics Pharmaceuticals, Inc. (CRNX).
• Impact on Stock Dynamics: Understanding the role these large investors play is crucial for predicting potential shifts in the stock price and the company's strategic direction.

While specific, real-time data on institutional ownership can fluctuate, here's how you can typically find this information:

• Financial News Providers: Reputable sources like Yahoo Finance, Bloomberg, and MarketWatch offer updated details on major shareholders.
• SEC Filings: Reviewing 13F filings with the Securities and Exchange Commission (SEC) provides a detailed quarterly snapshot of institutional holdings.
• Investor Relations: Checking Crinetics Pharmaceuticals, Inc. (CRNX)'s investor relations page on their website can provide insights and reports on ownership structure.

Institutional investors frequently adjust their holdings based on factors such as company performance, market conditions, and broader economic trends. Monitoring these changes can offer a glimpse into the collective wisdom of sophisticated investors regarding Crinetics Pharmaceuticals, Inc. (CRNX)'s prospects.

For more in-depth information, explore Crinetics Pharmaceuticals, Inc. (CRNX): History, Ownership, Mission, How It Works & Makes Money.

As of the latest available data, the top institutional holders of Crinetics Pharmaceuticals, Inc. (CRNX) include:

• Vanguard Group Inc.
• BlackRock Fund Advisors
• State Street Global Advisors, Inc.

These firms manage substantial assets and their investment decisions can significantly impact Crinetics Pharmaceuticals, Inc. (CRNX)'s market valuation.

Reviewing recent changes in ownership, it's important to note:

• Increase in Stakes: Some institutional investors may have increased their positions, signaling confidence in Crinetics Pharmaceuticals, Inc. (CRNX)'s growth potential.
• Decrease in Stakes: Conversely, others may have reduced their holdings, possibly due to concerns about performance or shifting investment strategies.

The collective actions of these major shareholders can drive volatility and influence long-term investment trends in Crinetics Pharmaceuticals, Inc. (CRNX).

The influence of institutional investors on Crinetics Pharmaceuticals, Inc. (CRNX) extends beyond stock price. Their involvement can shape corporate strategy through:

• Proxy Voting: Exercising their voting rights on key company decisions.
• Engagement with Management: Communicating directly with the management team to advocate for specific initiatives or changes.

By understanding the dynamics of institutional ownership, investors can gain a deeper appreciation of the factors driving Crinetics Pharmaceuticals, Inc. (CRNX)'s market behavior and strategic direction.

Disclaimer: The shareholding data and values presented here are approximate and based on the most recent available information, which may be subject to change. Always refer to official SEC filings and financial news sources for the most accurate and up-to-date details.

Crinetics Pharmaceuticals, Inc. (CRNX) Key Investors and Their Impact on Crinetics Pharmaceuticals, Inc. (CRNX)

Understanding who invests in Crinetics Pharmaceuticals, Inc. (CRNX) and why can offer valuable insights into the company's prospects. Examining notable investors, their influence, and recent moves provides a clearer picture of market sentiment and potential future directions for CRNX.

While specific, real-time data on all Crinetics Pharmaceuticals, Inc. (CRNX) investors and their direct impact on stock movements can fluctuate, here's a general overview based on available information and typical investor behavior:

• Notable Investors: Identifying key investors often involves looking at institutional ownership. These can include:
  • Vanguard Group: Typically holds a significant position in many publicly traded companies.
  • BlackRock: Another major asset manager with substantial holdings.
  • RA Capital Management: A healthcare-focused fund known for its investments in biotech companies.
  • State Street Corporation: A large institutional investor with diverse holdings.

These firms often hold shares in CRNX through various funds and investment vehicles.

• Investor Influence: The impact of these investors can be substantial:
  • Stability: Large institutional holdings can provide stability to the stock price, as these investors tend to have longer-term investment horizons.
  • Credibility: Their investment can lend credibility to Crinetics Pharmaceuticals, Inc. (CRNX), attracting other investors.
  • Voting Power: Significant shareholders have the power to influence company decisions through their voting rights on matters such as board elections and major corporate actions.

Activist investors, if present, can push for strategic changes to unlock value, such as:

• Operational improvements
• Asset sales
• Strategic shifts

However, as of now, there's no indication of activist investors involvement in Crinetics Pharmaceuticals, Inc. (CRNX).

Recent moves by major investors are crucial to monitor. Significant buying or selling activity can signal confidence or concern about the company's future. For instance:

• Increasing Stakes: If major investors have been consistently increasing their stakes, it suggests a bullish outlook on Crinetics Pharmaceuticals, Inc. (CRNX).
• Decreasing Stakes: Conversely, a reduction in holdings might indicate concerns about the company's prospects.

To stay updated on these moves, investors should regularly consult SEC filings (such as 13F filings), monitor financial news, and use tools that track institutional ownership changes.

Here is a sample table with hypothetical data to illustrate institutional ownership (as of the end of the 2024 fiscal year):

Institutional ownership in Crinetics Pharmaceuticals, Inc. (CRNX) demonstrates significant interest from major investment firms. Vanguard Group holds 2,500,000 shares, representing 5.2% ownership, having recently increased their position by 2%. BlackRock maintains a substantial stake with 2,200,000 shares, or 4.6% ownership, showing no recent changes. RA Capital Management possesses 1,800,000 shares, accounting for 3.8% ownership, but has decreased their position by 5%. State Street Corporation holds 1,500,000 shares, or 3.1% ownership, and increased their position by 3%. These movements reflect varying degrees of confidence and strategic adjustments among key institutional investors.

For further insights into Crinetics Pharmaceuticals, Inc. (CRNX)'s financial standing, consider exploring: Breaking Down Crinetics Pharmaceuticals, Inc. (CRNX) Financial Health: Key Insights for Investors

Crinetics Pharmaceuticals, Inc. (CRNX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Crinetics Pharmaceuticals, Inc. (CRNX). This involves analyzing the perspectives of major shareholders, recent market behavior, and insights from financial analysts.

Investor Sentiment:

The overall fund sentiment towards Crinetics Pharmaceuticals is positive. An increase in the number of funds or institutions reporting positions in Crinetics Pharmaceuticals suggests growing confidence in the company. As of March 25, 2025, 598 funds or institutions held positions in CRNX, an increase of 20 or 3.46% in the last quarter.

• The average portfolio weight dedicated to CRNX by all funds is 0.35%, reflecting a 3.70% increase.
• Total shares owned by institutions increased by 15.51% in the last three months, reaching 117,289K shares.

However, the put/call ratio of CRNX is 3.48, which may indicate a bearish outlook.

Key institutional shareholders and their recent activities include:

• Wellington Management Group Llp: Holds 6,951K shares, representing 7.47% ownership. They increased their holdings by 35.84% in the previous filing but decreased their portfolio allocation in CRNX by 77.17% over the last quarter.
• Driehaus Capital Management: Holds 6,141K shares, representing 6.60% ownership. They increased their holdings by 4.16% in the prior filing and increased their portfolio allocation in CRNX by 0.37% over the last quarter.
• Price T Rowe Associates: Holds 5,415K shares, representing 5.82% ownership. They increased their holdings by 8.68% in their prior filing and increased their portfolio allocation in CRNX by 9.70% over the last quarter.
• EcoR1 Capital: Holds 4,288K shares, representing 4.61% ownership, with no change in the last quarter.
• Farallon Capital Management: Holds 4,075K shares, representing 4.38% ownership. They significantly increased their holdings by 71.49% in their prior filing and boosted their portfolio allocation in CRNX by 263.69% over the last quarter.

Recent Market Reactions:

The stock market has reacted to various developments, including analyst ratings and company-specific news. For example, Jefferies upgraded Crinetics Pharmaceuticals stock from 'Hold' to 'Buy' on January 22, 2025, which was influenced by a decline in share price from $60 to around $38.76. This upgrade suggested a positive outlook, anticipating recovery and growth after the pullback in share price.

Crinetics Pharmaceuticals' stock reached a 52-week low of $31.81 on March 31, 2025, and further dipped to $24.7 on April 9, 2025, amid market challenges. However, positive clinical trial results can lead to significant surges in the stock price. For instance, the stock jumped 19.1% to $45.18 after the company reported positive results from its Phase 3 PATHFNDR-2 study in March 2024.

Analyst Perspectives:

Analysts' evaluations of Crinetics Pharmaceuticals vary, with price targets ranging from $55.55 to $105.00. The average one-year price target as of March 19, 2025, was $77.16, suggesting a potential upside of 114.68% from the closing price of $35.94 per share.

Recent analyst actions include:

• Stifel initiated coverage with a 'Buy' recommendation on March 25, 2025.
• Jefferies upgraded the stock to 'Buy' with a price target of $55.00 on January 22, 2025.
• Piper Sandler reiterated an 'Overweight' rating with a price target of $97.00 on January 8, 2025.

Analysts' insights often focus on the potential of Crinetics' drug candidates and their impact on future market opportunities. Jefferies, for example, noted that the market may be undervaluing the potential $1 billion opportunity for CAH treatment.

The following table summarizes recent analyst ratings and price targets:

For further insights into the company's financial well-being, consider exploring Breaking Down Crinetics Pharmaceuticals, Inc. (CRNX) Financial Health: Key Insights for Investors.